Costing juvenile idiopathic arthritis: Examining patient-based costs during the first year after diagnosis

Rheumatology

Volumn 47, Issue 7, 2008, Pages 985-990

  Thornton, Judith ^a,i   Lunt, M ^a   Ashcroft, D M ^b   Baildam, E ^c   Foster, H ^d   Davidson, J ^e   Gardner medwin, J ^f   Beresford, M W ^g   Symmons, D ^a   Thomson, W ^a   Elliott, R A ^h  

^a Division of Epidemiology and Health Sciences   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e Royal Hospital for Sick Children   (United Kingdom)

^f ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

^h UNIVERSITY OF NOTTINGHAM   (United Kingdom)

ⁱ ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Costing study; Economics; Inflammatory arthritis; Juvenile idiopathic arthritis

Indexed keywords

CORTICOSTEROID; METHOTREXATE;

ADOLESCENT; ARTICLE; CHILD; CHILD HEALTH CARE; COHORT ANALYSIS; CONSULTATION; COST BENEFIT ANALYSIS; DISEASE DURATION; DRUG COST; ECONOMIC EVALUATION; ENTHESITIS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYDROTHERAPY; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PHYSIOTHERAPY; POLYARTHRITIS; PRIORITY JOURNAL; UNITED KINGDOM;

ADOLESCENT; ANTIRHEUMATIC AGENTS; APPOINTMENTS AND SCHEDULES; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; DIAGNOSTIC SERVICES; DRUG COSTS; GREAT BRITAIN; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; INFANT; PROSPECTIVE STUDIES; REFERRAL AND CONSULTATION;

EID: 45749113368     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken039     Document Type: Article

References (21)

1. Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. J Am Med Assoc 2005;294:1671-84.
2. Cummins C, Connock M, Fry-Smith A, Burls A. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: Etanercept. Health Technol Assess 2002;6:1-43.
3. Epps H, Ginnelly L, Utley M et al. Is hydrotherapy cost-effective? A randomised controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis. Health Technol Assess 2005;9:iIi-iiv.
4. Minden K, Niewerth M, Listing J, Biedermann T, Schontube M, Zink A. Burden and cost of illness in patients with juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:836-42.
5. Allaire SH, DeNardo BS, Szer IS, Meenan RF, Schaller JG. The economic impacts of juvenile rheumatoid arthritis. J Rheumatol 1992;19:952-5.
6. Haapasaari J, Kautiainen HJ, Isomaki HA, Hakala M. Etanercept does not essentially increase the total costs of the treatment of refractory juvenile idiopathic arthritis. J Rheumatol 2004;31:2286-9.
7. Brunner HI, Barron AC, Graham TB et al. Effects of treatment on costs & health-related quality of life (HRQL) of children with polyarticular course juvenile rheumatoid arthritis (JRA). Arthritis Rheum 2004;50:S686.
8. Bernatsky S, Duffy C, Malleson P, Feldman DE, St Pierre Y, Clarke AE. Economic impact of juvenile idiopathic arthritis. Arthritis Rheum 2007;57:44-8.
9. Fink CW. Proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol 1995;22:1566-9.
10. Petty RE, Southwood TR, Baum J et al. Revision of the proposed classification oriteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998; 25:1991-4.
11. Petty RE, Southwood TR, Manners P et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
12. BMJ Publishing Group Ltd and Royal Pharmaceutical Society of Great Britain. British National Formulary for Children December 2005. London, UK: Pharmaceutical Press, 2005.
13. BMJ Publishing Group Ltd and Royal Pharmaceutical Society of Great Britain.British National Formulary December 2005. London, UK: Pharmaceutical Press, 2005.
14. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987;317:1098.
15. Lam TK, Leung DT. More on simplified calculation of body-surface area. N Engl J Med 1988;318:1130.
16. Elliott RA, Davies LM, Payne K, Moore JK, Harper NJ. Costing day case anesthesia: Obtaining accurate patient-based costs for adults and children. Int J Technol Assess Health Care 2004;20:552-61.
17. Curtis L, Netten A. Unit costs of health and social care. Canterbury: PSSRU University of Kent, 2005.
18. Barber JA, Thompson SG. Analysis of cost data in randomized trials: An application of the non-parametric bootstrap. Stat Mad 2000;19:3219-36.
19. Briggs A, Gray A. The distribution of health care costs and their statistical analysis for economic evaluation. J Health Serv Res Policy 1998;3:233-45.
20. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. 2004 http://www.nice.org.uk(download.aspx.?o= 201973 (1 May 2007, date last accessed).
21. Foster HE, Eltringham MS, Kay LJ, Friswell MS, Abinun M, Myers A. Delay in access to appropriate care for children presenting with musculoskeletal complaints and ultimately diagnosed as juvenile idiopathic arthritis. Arthritis Care Res 2007;57:921-7.